Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin alfa in healthy participants of Chinese, Japanese, and White/European ancestry
NCT07335198Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efimosfermin in non-alcoholic fatty liver disease (NAFLD) (6 arms), sponsored by GSK. Primary endpoints: Adverse Events at 90 days, Clinically significant changes in hematology, chemistry and urinalysis parameters at 90 days and 5 more. Started Mar 2026; status: completed.
02
Drugs
efimosfermin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07335198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335198.